Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2015, Article ID 629046, 4 pages
http://dx.doi.org/10.1155/2015/629046
Case Report

Clinical Outcome of Third-Line Pazopanib in a Patient with Metastatic Renal Cell Carcinoma

1Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology “Sapienza”, St. Andrea Hospital, Via di Grottarossa 1035-1030, 00189 Rome, Italy
2Department of Radiology, Faculty of Medicine and Psychology “Sapienza”, St. Andrea Hospital, Via di Grottarossa 1035-1030, 00189 Rome, Italy
3Department of Medical and Surgical Sciences and Translational Medicine, Faculty of Medicine and Psychology “Sapienza”, St. Andrea Hospital, Via di Grottarossa 1035-1030, 00189 Rome, Italy

Received 17 September 2015; Revised 15 November 2015; Accepted 30 November 2015

Academic Editor: Jorg Kleeff

Copyright © 2015 Michela Roberto et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. Renal cell carcinoma accounts for about 2-3% of all malignant tumors. The prevalence of brain metastases from RCC is less than 20% of cases. Traditionally, whole brain radiotherapy as well as the latest stereotactic radiosurgery improves both survival and local tumor control. These treatments also allow stabilization of clinical symptomatology. However, validated treatment guidelines for RCC patients with brain metastases are not yet available on account of the frequent exclusion of such patients from clinical trials. Moreover, limited data about the sequential use of three therapies, changing the class of agent, have been published up to now. Case Report. We report the case of a patient with metastatic RCC who developed disease progression after sunitinib and everolimus as first-line and second-line therapy, respectively. Thus, he underwent a multimodality treatment with pazopanib, as third-line therapy, to control systemic disease and radiosurgery directed on the new brain metastasis. To date, the patient is still receiving pazopanib, with progression-free survival and overall survival of 43 and 103 months, respectively. Conclusion. In a context characterized by different emerging options, with no general consensus on the optimal treatment strategy, the use of pazopanib in pretreated patients could be a suitable choice.